Key result
Beta-blockers remain first-line therapy for symptomatic and asymptomatic congenital LQTS, affecting ~1 in 2000 patients.
Why the study?
Although researched extensively since 1957, the genetic etiology of congenital long QT syndrome is still not fully understood.
Systematic Review
This review summarizes the pathophysiology, diagnosis, and management of congenital long QT syndrome, highlighting beta-blockers as the cornerstone of therapy.
Answers are grounded in this paper and cite their sources.
Beta-blockers remain first-line for congenital LQTS; reinforces established management across symptomatic and asymptomatic patients.
Congenital long QT syndrome (LQTS) is a disorder of myocardial repolarization defined by a prolonged QT interval on electrocardiogram (ECG) that can cause ventricular arrhythmias and lead to sudden cardiac death. LQTS was first described in 1957 and since then its genetic etiology has been researched in many studies, but it is still not fully understood. Depending on the type of monogenic mutation, LQTS is currently divided into 17 subtypes, with LQT1, LQT2, and LQT3 being the most common forms. Based on the results of a prospective study, it is suggested that the real prevalence of congenital LQTS is around 1:2000. Clinical manifestations of congenital LQTS include LQTS-attributable syncope, aborted cardiac arrest, and sudden cardiac death. Many patients with congenital LQTS will remain asymptomatic for life. The initial diagnostic evaluation of congenital LQTS includes obtaining detailed personal and multi-generation family history, physical examination, series of 12-lead ECG recordings, and calculation of the LQTS diagnostic score, called Schwartz score. Patients are also advised to undertake 24-hour ambulatory monitoring, treadmill/cycle stress testing, and LQTS genetic testing for definitive confirmation of the diagnosis. Currently available treatment options include lifestyle modifications, medication therapy with emphasis on beta-blockers, device therapy and surgical therapy, with beta-blockers being the first-line treatment option, both in symptomatic and asymptomatic patients.
No takes yet. Share an insight, caveat, or question.
Edvard Galić (2021) conducted a systematic review in Congenital Long QT Syndrome. Congenital long QT syndrome has an estimated prevalence of 1:2000 and is primarily managed with beta-blockers as the first-line treatment option for symptomatic and asymptomatic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: